Ver­tex doesn’t need to do more test­ing for rogue gene ed­its from sick­le cell ther­a­py tri­al, FDA ad­vi­sors say

Last year
R&D
FDA+

Cana­di­an gene ther­a­py biotech en­Gene starts trad­ing on Nas­daq af­ter com­plet­ing For­bion SPAC deal

Last year
Financing
Startups

As­traZeneca pays $25M up­front, $80M eq­ui­ty in­vest­ment in­to Cel­lec­tis for gene and cell ther­a­py pact

Last year
Deals
Cell/Gene Tx

Sanofi en­lists Ush­er, Robin Arzón, Adam Schefter to type 1 di­a­betes ear­ly screen­ing cause

Last year
Pharma
Marketing

Gen­er­a­tive AI biotech part­ners with can­cer cen­ter in bid to speed up CAR-T de­vel­op­ment in sol­id tu­mors

Last year
Deals
AI

Ap­n­imed and Sh­iono­gi cre­ate $150M joint ven­ture for sleep ap­nea

Last year
Financing
Deals

Vi­ro­Cell to op­er­ate from a Lon­don fa­cil­i­ty to man­u­fac­ture vi­ral vec­tors for clin­i­cal tri­als

Last year
Manufacturing

Up­dat­ed: Eu­ro­pean Com­mis­sion au­tho­rizes No­vavax's up­dat­ed Covid vac­cine

Last year
Pharma
FDA+

Nos­trum agrees to $50M set­tle­ment with DOJ over al­le­ga­tions of un­der­pay­ing Med­ic­aid

Last year
Pharma
Law

Pfiz­er shelves five mid- and ear­ly-stage pro­grams

Last year
Pharma

FDA push­es can­cer drug de­vel­op­ers to in­clude over­all sur­vival da­ta more fre­quent­ly

Last year
Pharma
FDA+

Long­time can­cer R&D chief Pe­ter Lebowitz is tak­ing his fi­nal bows at J&J on­col­o­gy. Now what?

Last year
Bioregnum
R&D

FDA lifts clin­i­cal hold on Mer­sana’s STING ag­o­nist, PhI start­ing dose low­ered af­ter pa­tient death

Last year
R&D

As In­dia grows its bi­o­log­ics mar­ket, Ara­gen builds new $30M fa­cil­i­ty

Last year
Manufacturing

As Sarep­ta ex­ecs talk up Duchenne con­fir­ma­to­ry tri­al re­sults, in­vestors and an­a­lysts re­main di­vid­ed on how flex­i­ble ...

Last year
R&D
FDA+

Galera con­sid­ers 's­trate­gic' op­tions; No­vo part­ners with French biotech; An­Heart gets $40M

Last year
News Briefing

GSK steps in for J&J’s li­cense of Ar­row­head’s he­pati­tis B drug, plans com­bo study with its own can­di­date

Last year
Deals
R&D

Lo­cal phar­ma­cies say they're strug­gling to af­ford GLP-1s

Last year
Health Tech

Catal­en­t's stock down af­ter Sarep­ta’s PhI­II Duchenne study miss­es pri­ma­ry end­point

Last year
Manufacturing

En­gine Bio­sciences bags $27M Se­ries A ex­ten­sion to ad­vance pre­ci­sion med­i­cine plat­form in on­col­o­gy

Last year
Financing
R&D

Glob­al dig­i­tal health fund­ing hits its low­est lev­el in al­most a decade

Last year
Health Tech

Mar­ket­ingRx roundup: In­smed, In­cyte rank as top sci­ence work­places; Mod­er­na, Bil­lie Jean King give vac­cine re­minder

Last year
Pharma
Marketing

Pfiz­er de­tails mR­NA flu vac­cine da­ta, but re­vis­es time­line

Last year
Pharma

Kite en­lists Epic Bio to ap­ply epi­ge­net­ic edit­ing in cre­at­ing next-gen CAR-T cells

Last year
Deals
Cell/Gene Tx
First page Previous page 253254255256257258259 Next page Last page
A service from the Financial Times